[1] Sumihiro N,Shigeki
S,Mitsuya H,et al. Discovery of canagliflozin,a novel C-glucoside with
thiophene ring,as sodium-dependent
glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes
mellitus[J]. J Med Chem,2010,53 (17): 6355- 6360.
[2] Tan XS, Ji LW, Zhang X.Progress in research
on the effect of sodium-glucose co-transporter2 inhibitors on cardio——vascular
system in diabetic patients [J].China journal of new drug,2020,29(2):152 -157.
[3] 马亭亭,李英.
SGLT2抑制剂防治糖尿病肾病的研究进展[J].临床荟萃,2019,34(7):668-672.
[4] 吕秋菊,钟怡,张晋.口服降糖药钠葡萄糖协同转运蛋白2抑制剂的研究进展[J].华西药学杂志,2017,32(3):326-329.
[5] 朱芳莹,董正伟,朱文渊,等. 糖尿病治疗药物及合成进展[J].发酵科技通讯,2016,45(3):175-181.
[6] 熊能,韦圣,胡忠策.
α-葡萄糖苷酶抑制剂的研究进展和趋势[J].发酵科技通讯,2018,47(1):58-64.
[7] 阿德·马吉德,奇肖姆,梅尔曼,等.可用作SGLT抑制剂的化合物的制备方法:中国,101801371A[P].2010-08-11.
[8] 菲利尔斯,布雷克斯,尼斯特,等.制备可用作SGLT抑制剂的化合物的方法:中国,103467439[P].2013-12-25.
[9] 陈洁,汪武卫,卡格列净合成路线图解[J] .中国药物化学杂志,2015,25(3):241-243.
[10] Bouder F.Regulating impurities in
pharmaceutical products:atolerability of risk
approach[J].Expert Rev Clin Pharmacol,2008,1(2):241-250.
[11] Mueller L,Mauthe
RJ,Riley CM,et al.A rationale for
determining, testing, and controlling specific impurities in pharmaceuticals
that possess potential for genotoxicity[J].Regul Toxicol Pharmacol,2006,44(3):198-211.
[12] 钟静,王娅平,冯卫生.卡格列净关键中间体合成研究[J].河南科学,2016,34(8):1241-12440.
[13] 陈轶嘉,胡楚红,王建伟.LC-MS/MS法测定卡格列净二甲双胍复方制剂基因毒杂质[J].发酵科技通讯,2021,50(2):114-118.
[14] 蔡锦雄,李美芳,梁爱仙,等.HS-GC法测定枸地氯雷他定原料药中12种有机溶剂的残留量[J].中国药物评价,2021,38(4):309-313.
[15] 金晶晶,李进,汪娟,等.毛细管气相色谱法同时测定卡格列净原料药中甲醇等6种有机溶剂残留量[J].沈阳药科大学学报,2016,33(5):369-372.
[16] 郝杰,张哲峰,毕小平.原料药杂质研究与控制浅析[J].中国现代应用药学,2015,32(6):757-763.
[17] 胡昌勤,张夏.化学药品杂质谱控制的现状与展望[J].药学学报,2019,54(12):2214-2231.
[18] 张慧敏,林建群,冯康彪,等.药品中遗传性杂质的评估和控制[J].中国现代应用药学,2014,31(9):1160-1166.
[19] 张玉英,李薇,潘卫松.
药品杂质遗传毒性评价的概述[J].药品评价,2021,18(4):203-207.
[20] 文海若,叶倩,于敏,等.杂质遗传毒性评价与研究方法[J].中国药物评价,2021,38(5):365-370.
|